OrthoCare (올쏘케어)
AI-based integrated platform for musculoskeletal diagnosis and rehabilitation
Website: https://orthocare.co.kr/
Cover Block
Open sources
| Field | Value |
|---|---|
| Company | OrthoCare (올쏘케어) |
| Tagline | AI-based integrated platform for musculoskeletal diagnosis and rehabilitation |
| Headquarters | Seoul, South Korea [Google Play, retrieved 2026] |
| Founded | 2024 [The VC] |
| Stage | Seed [Health Kyunghyang, June 2025] |
| Business model | Hardware + Software |
| Industry | Healthtech |
| Technology | AI / Machine Learning [FuturePlay] |
| Geography | East Asia |
| Growth profile | Venture Scale |
| Founding team | Academic Spinout [Health Kyunghyang, June 2025] |
| Funding label | Seed |
| Total disclosed funding | ~$3,180,000 [KORIT, October 2026] |
Links
Open sources
- Website: https://orthocare.co.kr
- Google Play: https://play.google.com/store/apps/details?id=kr.orthocare.anapa.mlkit
What an Investor Needs First
PUBLIC OrthoCare is a Seoul-based digital health startup building an AI-based platform for musculoskeletal diagnosis and rehabilitation, and it merits investor attention because the company is pairing a clinician-led orthopedic workflow with early product and financing signals in a category where clinical credibility matters more than surface-level software distribution [FuturePlay] [Health Kyunghyang, June 2025] [KORIT, October 2026]. Founded in 2024, the company appears to have emerged from an academic-clinical setting around Catholic University Yeouido St. Mary’s Hospital, with reporting indicating that CEO Kim Jong-ho prepared the business with support from the university’s industry-academic cooperation foundation before formal launch [Health Kyunghyang, June 2025] [The VC].
The product stack centers on ANAPA PS, a physician-facing measurement application, and ANAPA ME, a patient-facing rehabilitation app, together forming a system intended to connect in-clinic assessment with home-based postoperative exercise and follow-up [PMC] [CIOS] [FuturePlay]. That architecture is the main point of differentiation visible in public materials: rather than offering a standalone consumer rehab app, OrthoCare is positioning around objective measurement of shoulder range of motion and muscle strength alongside guided digital therapeutics for indications such as rotator-cuff repair recovery and frozen shoulder treatment [PubMed] [Health Kyunghyang, June 2025].
The founder profile is unusually aligned with the problem set. Kim is identified publicly as an orthopedic surgeon and professor at Catholic University Yeouido St. Mary’s Hospital, which lends domain relevance to both product design and early clinical access, although the public record remains thin on the broader commercial leadership bench [The VC] [LinkedIn].
On financing, the public record shows a June 2025 seed investment led by FuturePlay, followed by later capital associated with Taurus Partners and a pre-Series A financing of about $3.18 million disclosed in October 2026, though round labeling is not fully consistent across sources [Health Kyunghyang, June 2025] [The VC] [KORIT, October 2026]. The business model is best understood as hardware plus software, given the combination of hospital measurement tooling and a patient application, but the key questions for the next 12 to 18 months are whether the company can convert clinical validation into repeatable hospital adoption, secure clearer regulatory and commercialization milestones, and show stable team growth rather than the conflicting headcount snapshots now visible in public databases [FuturePlay] [Crustdata, January 2026] [The VC, September 2026].
Partially corroborated -- Core company identity, founder background, and product structure are corroborated across public databases and clinical literature, but several operating details and financing labels rely on single-source or company-linked reporting.
Taxonomy Snapshot
| Axis | Value |
|---|---|
| Stage | Seed |
| Business Model | Hardware + Software |
| Industry / Vertical | Healthtech |
| Technology Type | AI / Machine Learning |
| Geography | East Asia |
| Growth Profile | Venture Scale |
| Founding Team | Academic Spinout |
| Funding | Seed, total disclosed about $3,180,000 [KORIT, October 2026] |
Inside the Company
PUBLIC
OrthoCare presents as a young clinical spinout rather than a broad digital health roll-up. The company was founded in 2024 in Seoul and describes its work as an AI-based integrated platform for musculoskeletal diagnosis and rehabilitation, a framing that appears in investor and company materials rather than in a regulatory filing [FuturePlay]. Its listed address places the business at Yeouido St. Mary's Hospital in Seoul, which aligns with the academic-hospital roots visible elsewhere in the public record [Google Play, retrieved 2026].
The founding narrative is narrow but coherent in the sources that are public. Kim Jong-ho is identified as founder and CEO, and public profiles tie him to Catholic University Yeouido St. Mary's Hospital as an orthopedic surgeon and professor, which helps explain why the company's first product direction centers on postoperative and physician-guided rehabilitation rather than a consumer wellness angle [The VC] [LinkedIn, retrieved 2026].
The disclosed milestone trail is still short. FuturePlay lists OrthoCare in its portfolio, while the company's public website and app-store presence show the ANAPA branding already attached to its rehabilitation workflow, suggesting the business moved from incorporation into early product packaging quickly, even if broader commercialization details remain thin in public evidence [FuturePlay] [Google Play, retrieved 2026] [orthocare.co.kr].
Partially corroborated -- Based primarily on company materials, investor portfolio information, app-store listing data, and one startup database profile.
Under the Hood
Reported and inferred
OrthoCare is not presenting as a broad hospital software vendor at this stage. The public record points to a narrower clinical workflow: measuring recovery after orthopedic intervention, then extending rehabilitation into the home through a patient application. FuturePlay describes the company as developing an AI-based integrated platform for musculoskeletal diagnosis and rehabilitation, with two named product surfaces, ANAPA PS for hospital use and ANAPA ME for patient self-exercise [FuturePlay]. Health Kyunghyang adds that the initial focus is musculoskeletal digital therapeutics, specifically including rehabilitation after rotator-cuff repair and treatment of frozen shoulder, with a model that combines clinical measurement, physician-guided rehabilitation, and at-home digital exercises [Health Kyunghyang, June 2025].
The more useful evidence comes from the clinical literature, because it clarifies what each module appears to do in practice. The ANAPA digital therapeutic system is described in PMC and CIOS as consisting of ANAPA PS, a physician-facing measurement application, and ANAPA ME, a patient-facing mobile rehabilitation tool for home-based postoperative exercise and clinical efficacy evaluation [PMC, retrieved 2026] [CIOS, retrieved 2026]. PubMed reports that ANAPA PS's automated measurement functions demonstrated technical reliability and measurement consistency for monitoring rehabilitation outcomes, which supports the measurement layer more clearly than the broader company marketing does [PubMed, retrieved 2026]. That said, the available sources support technical functionality and early clinical use more than they support commercial deployment at scale, and the "AI-based" claim remains primarily company or investor framing rather than a publicly detailed model architecture [FuturePlay] [Health Kyunghyang, June 2025].
Partially corroborated -- Product structure is corroborated across FuturePlay, PMC, and CIOS, but several positioning claims remain company or investor sourced.
Market Research
PUBLIC
Musculoskeletal care is one of the larger unresolved cost centers in aging health systems, and OrthoCare is entering at a moment when providers and regulators are showing more willingness to test software-guided rehabilitation, even if the precise market size for its niche is not established in the public record [Health Kyunghyang, June 2025] [PMC] [PubMed].
The main constraint in sizing this market is evidentiary, not conceptual. No named third-party TAM, SAM, or SOM estimate for OrthoCare, or for Korean postoperative shoulder rehabilitation software specifically, appears in the source set. The nearest public framing comes from OrthoCare's own described scope: an AI-based platform for musculoskeletal diagnosis and rehabilitation, with an initial focus on digital therapeutics for rotator-cuff repair recovery and frozen shoulder care [FuturePlay] [Health Kyunghyang, June 2025]. That places the company at the intersection of several larger categories rather than in a neatly published standalone segment.
The demand signal in the public evidence is clinical workflow compression. OrthoCare's ANAPA system combines physician-side measurement with patient-side home exercise, and the cited pilot-study materials describe ANAPA PS as a tool for automated shoulder range-of-motion and muscle-strength assessment, while ANAPA ME supports home-based postoperative exercise and clinical efficacy evaluation [PMC] [CIOS] [PubMed]. If those functions hold up outside study settings, the commercial relevance is straightforward: postoperative rehabilitation is labor-intensive, adherence-sensitive, and often split between in-clinic assessment and unsupervised home recovery.
The public record also points to a regulatory and institutional tailwind, though it is still early. Health Kyunghyang's June 2025 reporting places OrthoCare within South Korea's digital-therapeutics push for musculoskeletal conditions and says the company had already run an exploratory clinical trial with Yeouido St. Mary's Hospital in January 2025 and signed an MOU with the Department of Orthopedic Surgery at Catholic University College of Medicine in February 2025 [Health Kyunghyang, June 2025]. KORIT's October 2026 funding report says the company planned to accelerate clinical and commercialization work with the Ministry of Food and Drug Safety, which suggests a market path shaped as much by evidence generation and device classification as by ordinary software distribution [KORIT, October 2026].
Adjacent markets matter here because OrthoCare does not need to own all of musculoskeletal care to matter commercially. The most relevant substitutes are conventional physical therapy, orthopedic rehabilitation protocols delivered without software, remote therapeutic monitoring tools, hospital measurement devices, and broader digital therapeutics platforms that cover chronic pain or mobility recovery rather than shoulder-specific rehabilitation [FuturePlay] [PMC] [CIOS]. In practice, the company is not selling against a single software category alone. It is asking hospitals and clinicians to replace pieces of manual assessment and informal home-exercise follow-up with a more structured digital loop.
| Market frame | Public evidence | Relevance to OrthoCare |
|---|---|---|
| Musculoskeletal digital therapeutics | Initial focus on rotator-cuff repair rehabilitation and frozen shoulder treatment [Health Kyunghyang, June 2025] | Core entry segment |
| Postoperative orthopedic rehabilitation | ANAPA ME used for home-based postoperative exercises [PMC] | Near-term use case with defined clinical workflow |
| Clinical assessment software for orthopedic care | ANAPA PS provides automated measurement of shoulder ROM and muscle strength [PMC] [PubMed] | Physician-side wedge into hospital workflows |
| Hospital-to-home rehab management | System combines clinical measurement with at-home digital exercises [Health Kyunghyang, June 2025] | Supports integrated hardware-plus-software positioning |
The table shows why the market discussion has to stay category-based for now. Public evidence is stronger on workflow fit and clinical setting than on segment size, which means market attractiveness rests less on headline TAM and more on whether a focused orthopedic rehabilitation product can convert institutional validation into repeat deployment.
Partially corroborated -- Section relies on named public sources for product-market fit, clinical context, and regulatory direction, but no independent third-party TAM/SAM/SOM sizing was available in the source set.
Competition and Substitutes
MIXED OrthoCare appears to sit at the intersection of three competitive lanes, orthopedic clinic workflow tools, postoperative rehabilitation apps, and digital therapeutics for musculoskeletal recovery, but the public record names the company more clearly than it names its rivals [FuturePlay] [Health Kyunghyang, June 2025] [PMC, retrieved 2026].
The segment map matters because OrthoCare is not selling into a vacuum. On one side are incumbent hospitals and rehabilitation departments that already manage shoulder range-of-motion checks, muscle-strength testing, and home exercise instructions through clinician labor and general-purpose software rather than a dedicated musculoskeletal platform [PMC, retrieved 2026]. On another side are digital rehabilitation and digital-therapeutic products that package home recovery into a mobile workflow, which is the lane OrthoCare is explicitly targeting through ANAPA ME and ANAPA PS for postoperative and frozen-shoulder use cases [Health Kyunghyang, June 2025] [CIOS, retrieved 2026]. A third lane comes from adjacent substitutes, including conventional physical therapy programs and physician-directed paper or video exercise protocols, which remain viable if the product does not show enough clinical or workflow advantage to change behavior [PMC, retrieved 2026].
The company’s edge today looks clinical rather than commercial. Kim Jong-ho is publicly identified as both founder and an orthopedic surgeon-professor at Catholic University Yeouido St. Mary’s Hospital, which gives OrthoCare domain credibility and a plausible route into clinical validation work that a generalist software team would have to build from scratch [The VC] [LinkedIn, retrieved 2026]. The product architecture also spans a physician-facing measurement layer and a patient-facing home rehabilitation layer, and the underlying ANAPA system has been described in published clinical literature rather than only in company materials, which is a meaningful signal in a regulated health category [PMC, retrieved 2026] [PubMed, retrieved 2026]. That edge is still perishable. If hospital access remains concentrated around the founder’s institutional network, larger rehabilitation software or device companies could replicate the workflow surface faster than OrthoCare can build distribution beyond early academic channels [Health Kyunghyang, June 2025].
The biggest exposure is that the company does not yet appear to own a broad channel. Public sources point to exploratory clinical work at Yeouido St. Mary’s Hospital in January 2025 and an MOU with the Department of Orthopedic Surgery at Catholic University College of Medicine in February 2025, but they do not establish multi-site commercial deployment, payer adoption, or a hospital sales footprint across South Korea [Health Kyunghyang, June 2025]. In practice, that means OrthoCare competes not only with named startups, which the public source set does not provide, but with incumbent care pathways that are already embedded in hospital routines. In categories like postoperative rehab, inertia is a serious competitor because the buyer often needs proof on outcomes, workflow burden, and reimbursement at the same time [PMC, retrieved 2026].
The most plausible 18-month scenario is less about outright category dominance and more about which model compounds evidence fastest. OrthoCare is the likely winner if clinically published measurement reliability and physician-guided home rehabilitation translate into repeat adoption beyond founder-linked institutions, because that would turn its current academic-spinout profile into a distribution asset rather than a narrow origin story [PubMed, retrieved 2026] [Health Kyunghyang, June 2025]. The likely loser, if hospital procurement continues to prefer existing rehabilitation workflows and general-purpose care delivery tools, is the standalone musculoskeletal DTx layer itself, because a dual-app architecture is harder to defend if clinicians view it as additive software rather than a necessary part of care [CIOS, retrieved 2026] [FuturePlay].
Partially corroborated -- The section relies on named public sources for OrthoCare's positioning, founder background, product architecture, and early clinical affiliations, but the source set does not name direct competitors, so parts of the competitive map rest on category-level inference from published product and study descriptions [FuturePlay] [Health Kyunghyang, June 2025] [PMC, retrieved 2026] [PubMed, retrieved 2026].
Opportunity
PUBLIC
The prize here is not a single rehab app, but a clinically anchored musculoskeletal care stack that could sit between orthopedic surgeons, hospital workflows, and patients recovering at home if OrthoCare can turn early product evidence into standard postoperative practice [FuturePlay] [Health Kyunghyang, June 2025] [PMC, retrieved 2026].
The headline opportunity is straightforward. OrthoCare is building both sides of the rehabilitation workflow, with ANAPA PS for physician-facing measurement and ANAPA ME for patient-facing home exercise, rather than entering as a narrow consumer app or a stand-alone device vendor [FuturePlay] [PMC, retrieved 2026] [CIOS, retrieved 2026]. That matters because musculoskeletal recovery is often fragmented across clinic measurement, physician instruction, and at-home adherence; the company's public materials and the published pilot-study descriptions suggest it is trying to connect those steps into one system, initially around shoulder rehabilitation after rotator-cuff repair and frozen shoulder treatment [Health Kyunghyang, June 2025] [PMC, retrieved 2026]. The outcome that looks reachable, if still early, is a category-relevant digital therapeutic and measurement platform for orthopedic rehabilitation in South Korea first, with room to widen into additional postoperative and chronic musculoskeletal pathways if clinical validation continues to accumulate [PubMed, retrieved 2026] [Innoforest, retrieved 2026].
The upside paths are clearer when broken into concrete operating scenarios rather than a single broad claim.
| Scenario | What happens | Catalyst | Why it's plausible |
|---|---|---|---|
| Shoulder rehab standard | OrthoCare becomes a preferred digital pathway for postoperative shoulder rehabilitation, pairing in-clinic ROM and strength measurement with guided home exercise | Additional clinical validation and hospital adoption around rotator-cuff repair and frozen shoulder workflows [Health Kyunghyang, June 2025] [PMC, retrieved 2026] | The company is already focused on these indications, and ANAPA PS and ANAPA ME are described in published study materials as the core system used for assessment and home rehabilitation [PMC, retrieved 2026] [CIOS, retrieved 2026] |
| Hospital workflow wedge | ANAPA PS becomes the entry point inside orthopedic clinics, with ANAPA ME attached as the follow-on patient engagement layer | Productization of physician-facing measurement into repeatable hospital workflows [FuturePlay] [PubMed, retrieved 2026] | Public sources describe ANAPA PS as a physician-facing tool for automated shoulder ROM and muscle-strength measurement, and PubMed-cited study coverage notes technical reliability and measurement consistency, which is the kind of evidence that can support clinical workflow adoption [FuturePlay] [PubMed, retrieved 2026] |
| Academic-to-commercial expansion | The company converts its university-hospital and surgeon relationships into a broader rehabilitation platform across affiliated institutions | Joint research and clinical-trial activity with Catholic University medical institutions, plus capital to accelerate clinical and commercial work [Health Kyunghyang, June 2025] [KORIT, October 2026] | Founder Kim Jong-ho is an orthopedic surgeon and professor at Catholic University Yeouido St. Mary's Hospital, and public reporting ties the company's early preparation and research links to that ecosystem [The VC] [Health Kyunghyang, June 2025] |
The compounding mechanism, if it appears, would come from tighter integration between measurement, prescription, and at-home execution. Each clinic using ANAPA PS could generate more standardized baseline and follow-up assessments, which in turn make ANAPA ME more useful as a guided extension of physician care rather than a generic exercise library [FuturePlay] [CIOS, retrieved 2026]. If the measurement layer continues to show reliability in published settings, OrthoCare could build a feedback loop in which more clinical usage improves protocol design, better protocols improve patient adherence and outcomes, and those outcomes make hospital adoption easier to justify [PubMed, retrieved 2026] [PMC, retrieved 2026]. The public evidence does not yet prove that flywheel at commercial scale, but the product architecture and early clinical framing are aligned with that model [FuturePlay] [Health Kyunghyang, June 2025].
The size of the win is harder to anchor because the available public record does not include a cited market-size study or a clean public-peer comparable in the source set. Even so, a credible upside frame is that a company owning both the clinical measurement layer and the home-rehabilitation layer in a high-volume orthopedic category could become a meaningful strategic asset to hospital systems, digital-therapeutics buyers, or medtech acquirers if it establishes evidence-led adoption in one indication and expands from there [PMC, retrieved 2026] [KORIT, October 2026]. Put more concretely, if the "Shoulder rehab standard" scenario plays out and broadens into adjacent musculoskeletal pathways, the company could support venture-scale outcomes in Korea's digital health market and potentially beyond, particularly because the platform is being built around physician workflow and clinical assessment rather than a consumer wellness model (scenario, not a forecast) [FuturePlay] [The VC] [PubMed, retrieved 2026].
Partially corroborated -- Supported by public company, clinical-study, and startup-database sources, but the core commercial upside case remains partly inferential and several operating claims are corroborated by only one independent public source.
Sources
Open sources
[Google Play, retrieved 2026] 아나파 -AI카메라로 쉽게 따라할 수 있는 재활운동 - Apps on Google Play | https://play.google.com/store/apps/details?id=kr.orthocare.anapa.mlkit
[The VC] The VC | https://thevc.kr/orthocare
[Health Kyunghyang, June 2025] 가톨릭대 교원 창업기업 올쏘케어, 근골격계질환 디지털 … | https://orthocare.co.kr/18/?bmode=view&idx=166254330
[FuturePlay] FuturePlay, company portfolio | https://futureplay.co/our-companies/11
[KORIT, October 2026] オルソケア、34億ウォン規模のプレシリーズA資金調達を完了…筋骨格系DTx、食品医薬品安全処の臨床・商用化を加速 | https://www.korit.jp/funding/healthcare/besuccess-orthocare-ai-dtx-261024/
[PMC, retrieved 2026] Digital Therapeutics for Postoperative Rehabilitation after Arthroscopic Rotator Cuff Repair: A Single-Center, Assessor-Blinded, Randomized Pilot Study - PMC | https://pmc.ncbi.nlm.nih.gov/articles/PMC13437144/
[CIOS, retrieved 2026] Digital Therapeutics for Postoperative Rehabilitation after Arthroscopic Rotator Cuff Repair: A Single-Center, Assessor-Blinded, Randomized Pilot Study - :: CIOS :: Clinics in Orthopedic Surgery | https://ecios.org/DOIx.php?id=10.4055%2Fcios25474
[PubMed, retrieved 2026] Digital Therapeutics for Postoperative Rehabilitation after Arthroscopic Rotator Cuff Repair: A Single-Center, Assessor-Blinded, Randomized Pilot Study - PubMed | https://pubmed.ncbi.nlm.nih.gov/42553900/
[LinkedIn, retrieved 2026] Jong-Ho Kim - South Korea | Professional Profile | LinkedIn | https://www.linkedin.com/in/jong-ho-kim-7507aa169/
[orthocare.co.kr] 제품/서비스 | https://orthocare.co.kr/16
[Crustdata, January 2026] OrthoCare Medical Equipment , Headcount, Funding & Open Jobs |… | https://profiles.crustdata.com/company/orthocare-medical-equipment
[The VC, September 2026] The VC | https://thevc.kr/orthocare
[Innoforest, retrieved 2026] 올쏘케어(아나파) - 기업정보 및 매출·투자·고용 데이터 | https://www.innoforest.co.kr/company/CP00022108/%EC%98%AC%EC%8F%98%EC%BC%80%EC%96%B4
Articles about OrthoCare (올쏘케어)
- OrthoCare's AI Puts a Physical Therapist in the Post-Op Patient's Pocket — With $3.2 million in fresh capital, the Seoul-based startup is advancing a two-part digital therapeutic for shoulder surgery recovery, aiming for regulatory clearance.